Editor’s Picks
AARC Annual Meeting 2022
March 11, 2022 (NEW ORLEANS, LA) – StemExpress is excited to attend the AACR Annual Meeting, April 8-13, 2022, where we will join the innovative minds in the clinical space to discuss the importance of picking partners from product development to clinical commercialization. As more cancer therapies move through clinical approval, our company mission is…
For More InformationCGT Global Opens Facility In Northern Nevada
RENO, Nev., April 5, 2021 /PRNewswire/ — StemExpress is excited to announce that we will be opening our eighth facility with our newest location in Reno, Nevada. The property development will include a state-of-the-art cell collection center as well as a large-scale warehouse that contains a centralized shipping location for the company. The site will also be a new…
For More InformationEarly Detection of Cancer from a Single Blood Draw
How can a single blood draw detect cancer early in disease progression? The National Cancer Institute estimates 1,735,350 new cases of cancers with mortality exceeding 600,000 this year in the US alone. It is therefore imperative to find an early detection system and effective treatment of these cancers to help ease the mortality rate. Early…
For More InformationChoosing a Biospecimen Provider
Imagine the following scenario. You are close to finalizing the development of a new drug or assay before it enters into clinical trials. However, you encounter a slight setback which requires specific cells you are evaluating to be retested in a key experiment….and you don’t have any vials left! These cells are from a unique…
For More InformationSurvival and Proliferation of Human NK Cells in Humanized Mice
Natural killer (NK) cells play a critical role in the innate immune system and represent the first line of defense against pathogens and tumor cells. Involved in immune surveillance, NK cells patrol the body looking for infected or cancerous cells. While other immune cells recognize the presence of antibodies on the MHC receptor of infected…
For More InformationPotential of CRISPR-Cas9-based Technology to Treat Congenital Amegakaryocytic Thrombocytopenia (CAMT)
A single mutation in a gene can lead to rare inherited diseases, such as cystic fibrosis, Tay-Sachs, and sickle-cell anemia, and are often difficult to treat and, for most, have no cure. However, with the current advances in CRISPR-Cas9 genome engineering technology, it may be possible to introduce new immunotherapies to treat these and other…
For More Information